Clincosm LogoSign in Get a demo

Expanded Access for CC-10004

Sponsor
Amgen (Industry)
Overall Status
No longer available
CT.gov ID
NCT03740516
Collaborator
(none)
1
Location

Study Details

Study Description

Brief Summary

This is an expanded access program (EAP) for eligible participants designed to provide access to CC-10004.

Condition or Disease Intervention/Treatment Phase

Study Design

Study Type:
Expanded Access
Official Title:
Expanded Access for CC-10004

Outcome Measures

Primary Outcome Measures

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    All
    Inclusion Criteria:
    Exclusion Criteria:

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Celgene Summit New Jersey United States 07901

    Sponsors and Collaborators

    • Amgen

    Investigators

    • Study Director: MD, Amgen

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Amgen
    ClinicalTrials.gov Identifier:
    NCT03740516
    Other Study ID Numbers:
    • CC-10004
    First Posted:
    Nov 14, 2018
    Last Update Posted:
    Apr 29, 2020
    Last Verified:
    Apr 1, 2020
    Keywords provided by Amgen
    Expanded Access
    Compassionate Use
    Additional relevant MeSH terms:
    Apremilast

    Study Results

    No Results Posted as of Apr 29, 2020